Vascular dermatan sulfate and heparin cofactor II

Area of Science:

• Biochemistry
• Vascular Biology
• Serpin Biology

Background:

• Heparin cofactor II (HCII) is a serpin superfamily protease inhibitor.
• HCII inactivates thrombin, a key enzyme in blood coagulation.
• Dermatan sulfate (DS) significantly enhances HCII's thrombin inhibition rate.

Purpose of the Study:

• To investigate the role of HCII in the physiological response to arterial injury.
• To determine the impact of HCII deficiency on thrombosis and atherosclerosis development.
• To evaluate HCII as a potential biomarker for vascular disease risk.

Main Methods:

• Utilized a mouse model lacking HCII (HCII-deficient mice).
• Induced arterial injury via oxidative damage to the endothelium and mechanical injury.
• Assessed thrombosis, neointima formation, and atherosclerotic lesion development.
• Correlated plasma HCII levels with human atherosclerosis and in-stent restenosis risk.

Main Results:

• HCII-deficient mice exhibited accelerated carotid artery thrombosis after endothelial oxidative damage.
• These mice showed increased arterial neointima formation post-mechanical injury.
• Hypercholesterolemic HCII-deficient mice developed more extensive atherosclerotic lesions.
• Low plasma HCII levels were identified as a risk factor for human atherosclerosis and in-stent restenosis.

Conclusions:

• The HCII-dermatan sulfate (DS) system plays a critical role in regulating the vascular response to injury.
• HCII deficiency exacerbates thrombosis and atherosclerosis, highlighting its protective function in arteries.
• HCII is a significant factor in preventing adverse vascular remodeling and disease progression.